Drugs / double mutant E. coli heat labile toxin (dmLT)
double mutant E. coli heat labile toxin (dmLT)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03038243 | Aug 2017 → Dec 2018 | shigellosis | PATH | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | double mutant E. coli heat labile toxin (dmLT) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03038243 ↗ |
| Modality | Protein / enzyme biologic | “double mutant E. coli heat labile toxin (dmLT)” NCT03038243 ↗ |
| Route | Oral | “2.25 x 10\^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56” NCT03038243 ↗ |